Novo Nordisk Is Scaling a Barrier to Growth. Should You Buy Its Stock Now?

With best-selling medicines for type 2 diabetes and obesity in hand, Novo Nordisk (NVO 2.37%) isn't content to let the chips fall where they may when it comes to patients having access to Ozempic and Wegovy. Thanks to the two drugs becoming a social phenomenon in the developed world, demand is running far above the company's ability to supply doses, potentially crimping its pace of revenue growth.But where there's a shortage, there's money to be made in closing the gap, and that's exactly what Novo Nordisk ...